Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

Bone Marrow Transplantation volume 50, pages 1037–1056 (2015)Cite this article

Subjects

Abstract

This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred in the field of haematopoietic SCT over the last years. Cord blood units as well as haploidentical donors have been increasingly used as stem cell sources for allo-SCT, thus, augmenting the possibility of finding a suitable donor for a patient. Continuous refinement of conditioning strategies has also expanded not only the number of potential indications but also has permitted consideration of older patients or those with co-morbidity for a transplant. There is accumulating evidence of the role of haematopoietic SCT in non-haematological disorders such as autoimmune diseases. On the other hand, the advent of new drugs and very effective targeted therapy has challenged the role of SCT in some instances or at least, modified its position in the treatment armamentarium of a given patient. An updated report with revised tables and operating definitions is presented.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schmitz N, Gratwohl A, Goldman JM . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 471–477.

    CAS  PubMed  Google Scholar 

  2. Goldman JM, Schmitz N, Niethammer D, Gratwohl A . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 1–7.

    CAS  PubMed  Google Scholar 

  3. Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639–646.

    CAS  PubMed  Google Scholar 

  4. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439–449.

    CAS  PubMed  Google Scholar 

  5. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    CAS  PubMed  Google Scholar 

  6. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576–4583.

    CAS  PubMed  Google Scholar 

  7. Ferrara GB, Bacigalupo A, Lamparelli T, Lanino E, Delfino L, Morabito A et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001; 98: 3150–3155.

    CAS  PubMed  Google Scholar 

  8. Bacigalupo A . A closer look at permissive HLA mismatch. Blood 2013; 122: 3555–3556.

    CAS  PubMed  Google Scholar 

  9. Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 2013; 122: 3651–3658.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Fleischhauer K, Locatelli F, Zecca M, Orofino MG, Giardini C, De Stefano P et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006; 107: 2984–2992.

    CAS  PubMed  Google Scholar 

  11. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–771.

    CAS  PubMed  Google Scholar 

  12. Trigg ME, Gingrich R, Goeken N, de Alarcon P, Klugman M, Padley D et al. Low rejection rate when using unrelated or haploidentical donors for children with leukemia undergoing marrow transplantation. Bone Marrow Transplant 1989; 4: 431–437.

    CAS  PubMed  Google Scholar 

  13. Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B et al. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol 1985; 13: 1201–1210.

    CAS  PubMed  Google Scholar 

  14. Henslee-Downey PJ, Parrish RS, Macdonald JS, Romond EH, Marciniak E, Coffey C et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 1996; 61: 738–745.

    CAS  PubMed  Google Scholar 

  15. Aversa F, Tabilio A, Velardi A, Terenzi A, Falzetti F, Carotti A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    CAS  PubMed  Google Scholar 

  16. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    PubMed  Google Scholar 

  17. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.

    CAS  PubMed  Google Scholar 

  18. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777–783.

    CAS  PubMed  Google Scholar 

  19. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size. An analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Blood 2010; 115: 3437–3446.

    CAS  PubMed  Google Scholar 

  20. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ et al. Comparison of outcomes of HLA matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008; 14: 1279–1287.

    PubMed  PubMed Central  Google Scholar 

  22. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.

    CAS  PubMed  Google Scholar 

  23. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008; 14: 748–758.

    PubMed  PubMed Central  Google Scholar 

  24. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  PubMed  Google Scholar 

  25. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  PubMed  Google Scholar 

  26. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52–58.

    CAS  PubMed  Google Scholar 

  27. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288–4290.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397–1400.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 2014; 99: 811–820.

    PubMed  PubMed Central  Google Scholar 

  30. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.

    CAS  PubMed  Google Scholar 

  31. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369: 1947–1954.

    PubMed  Google Scholar 

  32. Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengeloev H, Finke J et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 2014; 99: 370–377.

    PubMed  PubMed Central  Google Scholar 

  33. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343–1347.

    CAS  PubMed  Google Scholar 

  34. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113: 2410–2415.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009; 27: 256–263.

    PubMed  Google Scholar 

  36. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693–4699.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Rocha V, Rio B, Garnier F et al. Reduced intensity conditioning regimen in single unrelated cord blood transplantation in adults with hematological malignant disorders. A Eurocord-Netcord and SFGM-TC Survey [abstract] Blood (ASH Annual Meeting Abstracts) 2006; 108: 3143.

    Google Scholar 

  38. Miyakoshi S, Kami M, Tanimoto T, Yamaguchi T, Narimatsu H, Kusumi E et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Transplantation 2007; 84: 316–322.

    CAS  PubMed  Google Scholar 

  39. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011; 46: 659–667.

    CAS  PubMed  Google Scholar 

  40. Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE et al. Reduced intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119: 5591–5598.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Fernández MN, Regidor C, Cabrera R, García-Marco JA, Forés R, Sanjuán I et al. Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol 2003; 31: 535–544.

    PubMed  Google Scholar 

  42. Sánchez-Ortega I, Arnan M, Patiño B, Herrero MJ, Querol S, Duarte RF . Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia. Bone Marrow Transplant 2014; 49: 145–147.

    PubMed  Google Scholar 

  43. Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Serrano D, Anguita J et al. Haplo-cord transplantation using CD34 cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant 2014; 20: 2015–2022.

    CAS  PubMed  Google Scholar 

  44. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    Article  CAS  PubMed  Google Scholar 

  45. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462.

    CAS  PubMed  Google Scholar 

  46. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48: 761–770.

    CAS  PubMed  Google Scholar 

  47. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood 2014; 123: 1615–1620.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 2060–2067.

    CAS  PubMed  Google Scholar 

  49. Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035–1044.

    PubMed  Google Scholar 

  50. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    CAS  PubMed  Google Scholar 

  51. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284–292.

    PubMed  Google Scholar 

  52. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770–790.

    CAS  PubMed  Google Scholar 

  53. Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 2071–2074.

    PubMed  Google Scholar 

  54. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.

    PubMed  Google Scholar 

  56. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246–4254.

    PubMed  Google Scholar 

  57. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R . Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446–452.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014; 20: 402–408.

    PubMed  Google Scholar 

  59. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-Age Index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249–3256.

    PubMed  PubMed Central  Google Scholar 

  60. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 2011; 29: 1980–1986.

    PubMed  Google Scholar 

  61. Gratwohl A, Brand R, McGrath E, van Biezen A, Sureda A, Ljungman P et al. Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica 2014; 99: 908–915.

    PubMed  PubMed Central  Google Scholar 

  62. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 3183–3188.

    PubMed  Google Scholar 

  63. Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013; 122: 1576–1582.

    CAS  PubMed  Google Scholar 

  64. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

    CAS  PubMed  Google Scholar 

  65. Nagler A, Labopin M, Gorin NC, Ferrara F, Sanz MA, Wu D et al. Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014; 99: 1380–1386.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31: 3889–3897.

    PubMed  Google Scholar 

  67. Messina C, Candoni A, Carrabba MG, Tresoldi C, Sala E, Tassara M et al. Wilms tumor gene 1 transcript levels in leukapheresis of peripheral blood haematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: 1586–1591.

    CAS  PubMed  Google Scholar 

  68. Hourigan CS, McCarthy P, de Lima M . Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 154–163.

    PubMed  Google Scholar 

  69. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037–6042.

    CAS  PubMed  Google Scholar 

  70. Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 2014; 32: 1586–1594.

    PubMed  PubMed Central  Google Scholar 

  71. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS et al, Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010; 116: 3129–3139.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Keating A, DaSilva G, Perez WS, Gupta V, Cutler CS, Ballen KK et al. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica 2013; 98: 185–192.

    PubMed  PubMed Central  Google Scholar 

  73. Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant 2014; 20: 1021–1025.

    PubMed  Google Scholar 

  74. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013; 121: 3095–3102.

    CAS  PubMed  Google Scholar 

  75. Watts JM, Tallman MS . Acute promyelocytic leukemia: What is the new standard of care? Blood Rev 2014; 28: 205–212.

    PubMed  Google Scholar 

  76. Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 2014; 99: 111–115.

    PubMed  PubMed Central  Google Scholar 

  77. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113: 1375–1382.

    CAS  PubMed  Google Scholar 

  78. Gorin NC, Labopin M, Polge E, Cordonnier C, Jouet JP, Michallet M et al. Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003; 17: 1596–1599.

    PubMed  Google Scholar 

  79. Gupta V, Richards S, Rowe J . Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013; 121: 339–350.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Giebel S, Labopin M, Gorin NC, Caillot D, Leguay T, Schaap N et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer 2014; 50: 411–417.

    PubMed  Google Scholar 

  81. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002; 100: 1641–1647.

    CAS  PubMed  Google Scholar 

  82. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.

    CAS  PubMed  Google Scholar 

  83. Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. A Study of the MPN-Subcommittee of the CMWP of the EBMT. Biol Blood Marrow Transplant 2014; 20: 279–281.

    PubMed  Google Scholar 

  84. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264–5270.

    PubMed  Google Scholar 

  85. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.

    PubMed  Google Scholar 

  86. Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 2003; 17: 859–868.

    CAS  PubMed  Google Scholar 

  87. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17.

    CAS  PubMed  Google Scholar 

  88. Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P et al. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 2014; 25: 200–206.

    CAS  PubMed  Google Scholar 

  89. Gisselbrecht C, Schmitz N, Mounier N, Singh GD, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012; 18: 788–793.

    PubMed  Google Scholar 

  91. Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561–576.

    CAS  PubMed  Google Scholar 

  92. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012; 13: 1250–1259.

    CAS  PubMed  Google Scholar 

  93. Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2014; 29: 464–473.

    PubMed  Google Scholar 

  94. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342–1348.

    PubMed  Google Scholar 

  95. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. Ann Hematol 2012; 91: 931–940.

    PubMed  Google Scholar 

  96. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 757–766.

    CAS  PubMed  Google Scholar 

  97. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, Lopez-Guillermo A et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013; 98: 1014–1021.

    PubMed  PubMed Central  Google Scholar 

  98. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013.

    CAS  PubMed  Google Scholar 

  99. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554–2559.

    PubMed  Google Scholar 

  100. Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2013; 31: 1624–1630.

    CAS  PubMed  Google Scholar 

  101. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554–563.

    PubMed  PubMed Central  Google Scholar 

  102. Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 1409–1414.

    CAS  PubMed  Google Scholar 

  103. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011; 17: 1051–1057.

    PubMed  Google Scholar 

  104. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695–3700.

    PubMed  Google Scholar 

  105. Dreger P, Schmitz N . Autologous stem cell transplantation as part of first-line treatment of Waldenstrom's Macroglobulinemia. Biol Blood Marrow Transplant 2007; 13: 623–624.

    PubMed  Google Scholar 

  106. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227–2232.

    CAS  PubMed  Google Scholar 

  107. Dimopoulos M, Kastrdis E, Owen RG, Kyle RA, Landgren O, Morra E et al. Treatment recommendations for patients with Waldenstrom macroglobyulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124: 1404–1411.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N et al. Allogeneic stem-cell transplantation in patients with waldenstrom macroglobulinemia: report from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2010; 28: 4926–4934.

    PubMed  Google Scholar 

  109. Garnier A, Robin M, Larosa F, Golmard JL, Le GS, Coiteux V et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010; 95: 950–955.

    PubMed  PubMed Central  Google Scholar 

  110. Buske C, Leblond V . How to manage Waldenstrom's macroglobulinemia. Leukemia 2013; 27: 762–772.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.

    CAS  PubMed  Google Scholar 

  112. Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trumper L, Hallek M et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114: 880.

    Google Scholar 

  113. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.

    Google Scholar 

  114. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166–171.

    CAS  PubMed  Google Scholar 

  116. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4452.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014; 32: 273–281.

    PubMed  Google Scholar 

  118. Dietrich S, Tielesch B, Rieger M, Nickelsen M, Pott C, Witzens-Harig M et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 2011; 117: 1901–1910.

    PubMed  Google Scholar 

  119. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106–113.

    CAS  PubMed  Google Scholar 

  121. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093–3099.

    CAS  PubMed  Google Scholar 

  122. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857–877.

    CAS  PubMed  Google Scholar 

  123. Smith SM, Burns LJ, van BK, Lerademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31: 3100–3109.

    PubMed  PubMed Central  Google Scholar 

  124. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009; 27: 3951–3958.

    PubMed  Google Scholar 

  125. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    PubMed  Google Scholar 

  126. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.

    CAS  PubMed  Google Scholar 

  127. Bradford PT, Devesa SS, Anderson WF, Toro JR . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064–5073.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Whittaker SJ, Marsden JR, Spittle M, Russell-Jones R . Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Groups guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095–1107.

    CAS  PubMed  Google Scholar 

  129. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH . Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach. J Natl Compr Canc Net 2008; 6: 436–442.

    Google Scholar 

  130. Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 2013; 49: 2859–2868.

    CAS  PubMed  Google Scholar 

  131. Duarte RF, Schmitz N, Servitje O, Sureda A . Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008; 41: 597–604.

    CAS  PubMed  Google Scholar 

  132. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28: 4492–4499.

    PubMed  Google Scholar 

  133. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014; 32: 3347–3348.

    PubMed  Google Scholar 

  134. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.

    CAS  PubMed  Google Scholar 

  135. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    CAS  PubMed  Google Scholar 

  136. Martinez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013; 24: 2430–2434.

    CAS  PubMed  Google Scholar 

  137. Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 2013; 98: 1185–1195.

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensityconditioning in patients with relapsed or refractory Hodgkin'slymphoma. Results of the HDR-ALLO study—a prospectiveclinical trial by the Grupo Espanol de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party ofthe European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310–317.

    PubMed  PubMed Central  Google Scholar 

  139. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671–3677.

    CAS  PubMed  Google Scholar 

  140. Messer M, Steinzen A, Vervolgyi E, Lerch C, Richter B, Dreger P et al. Unrelated and alternative donor allogeneic stem cell transplantation in patients with relapsed or refractory Hodgkin's lymphoma: a systematic review. Leuk Lymphoma 2014; 55: 296–306.

    CAS  PubMed  Google Scholar 

  141. Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013; 98: 1467–1475.

    PubMed  PubMed Central  Google Scholar 

  142. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782–1791.

    CAS  PubMed  Google Scholar 

  143. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770–1781.

    CAS  PubMed  PubMed Central  Google Scholar 

  144. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18: 773–779.

    PubMed  Google Scholar 

  145. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120.

    CAS  PubMed  Google Scholar 

  146. Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.

    CAS  PubMed  Google Scholar 

  147. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591–3593.

    CAS  PubMed  Google Scholar 

  148. Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 2012; 18: 617–626.

    CAS  PubMed  Google Scholar 

  149. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093.

    CAS  PubMed  Google Scholar 

  150. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43–70.

    CAS  PubMed  Google Scholar 

  151. Scheinberg P, Young NS . How I treat acquired aplastic anemia. Blood 2012; 120: 1185–1196.

    CAS  PubMed  PubMed Central  Google Scholar 

  152. EBMT 2012 Handbook, 6th Edition, available at www.ebmt.org.

  153. Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M et al. Bone marrow versus peripheral blood matched sibling transplants, in acquired aplastic anemia: survival advantage for marrow in all age groups. Haematologica 2012; 97: 1142–1148.

    CAS  PubMed  PubMed Central  Google Scholar 

  154. Bacigalupo A, Marsh JC . Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013; 48: 198–200.

    CAS  PubMed  Google Scholar 

  155. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anaemia. Blood 2011; 118: 2351–2357.

    CAS  PubMed  Google Scholar 

  156. Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ et al. Retrospective study of Alemtuzumab versus ATG based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anaemia: a study from the British Society for Blood and Marrow Transplantation (BSBMT). Bone Marrow Transplant 2014; 49: 42–48.

    CAS  PubMed  Google Scholar 

  157. Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anaemia. A study by Eurocord and the Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2011; 17: 78–85.

    PubMed  Google Scholar 

  158. De Latour RP, Rocha V, Socie G . Cord blood transplantation in aplastic anaemia. Bone Marrow Transplant 2013; 48: 201–201.

    Google Scholar 

  159. Ciceri F, Lupo-Stanghellini MT, Korthof ET . Haploidentical transplantation in patients with acquired aplastic anaemia. Bone Marrow Transplantation 2013; 48: 183–185.

    CAS  PubMed  Google Scholar 

  160. Clay J, Kulasekarara AG, Potter V, Grimaldi F, McLornan D, Raj K et al. Non-myeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant 2014; 20: 1711–1716.

    PubMed  Google Scholar 

  161. De Latour RP, Schrezenmeier H, Bacigalupo A, Blaise D et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012; 97: 1666–1673.

    PubMed Central  Google Scholar 

  162. Brodsky RA . Paroxysmal nocturnal hemoglobinuria. Blood 2014; 124: 2804–2811.

    CAS  PubMed  PubMed Central  Google Scholar 

  163. Medeiros C, Zaris-Neto J, Pasquini R . Bone marrow transplantation for patients with Fanconi anaemia: reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transplant 1999; 24: 849–852.

    CAS  PubMed  Google Scholar 

  164. De Latour RP, Porcher R, Dalle J-H, Aljurf M, Korthof ET, Svahn J et al. Allogeneic haemopoietic stem cell transplantation in Fanconi anaemia: the European Group for Blood and Bone Marrow Transplantation experience. Blood 2013; 122: 4279–4286.

    Google Scholar 

  165. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenital. Biol Blood Marrow Transplant 2013; 19: 1238–1243.

    PubMed  PubMed Central  Google Scholar 

  166. Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant 2013; 48: 1168–1172.

    CAS  PubMed  Google Scholar 

  167. Martino M, Bottini A, Rosti G, Generali D, Secondino S, Barni S et al. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opin Biol Ther 2012; 12: 1505–1515.

    CAS  PubMed  Google Scholar 

  168. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S et al. High dose chemotherapy with autologous stem cell support versus standard-dose chemotherapy: Overview of individual patient data from 15 randomized adjuvant therapy breast cancer trials. J Clin Oncol 2011; 29: 3214–3223.

    CAS  PubMed  PubMed Central  Google Scholar 

  169. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet 2005; 366: 1935–1944.

    CAS  PubMed  Google Scholar 

  170. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE et al. Efficacy of high-dose alkylating chemotherapy in HER2/ neu-negative breast cancer. Ann Oncol 2006; 17: 588–596.

    CAS  PubMed  Google Scholar 

  171. Pedrazzoli P, Martino M, Delfanti S, Generali D, Bregni M, Lanza F et al. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in high-risk breast cancer patients. J Nat Cancer Inst 2014; 20: 501–506.

    CAS  Google Scholar 

  172. Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C et al. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant 2013; 48: 414–418.

    CAS  PubMed  Google Scholar 

  173. Simonelli M, Rosti G, Banna GL, Pedrazzoli P . Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol 2012; 23: 815–822.

    CAS  PubMed  Google Scholar 

  174. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340–348.

    CAS  PubMed  Google Scholar 

  175. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013; 24: 878–888.

    CAS  PubMed  Google Scholar 

  176. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178–2184.

    PubMed  Google Scholar 

  177. Ledermann JA . Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Int J Gynecol Cancer 2008; 18 (Suppl 1): 53–58.

    PubMed  Google Scholar 

  178. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008; 100: 533–541.

    CAS  PubMed  Google Scholar 

  179. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006; 17: 1479–1488.

    CAS  PubMed  Google Scholar 

  180. NCCN guidelines version 1Bone cancer http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf 2014.

  181. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284–3291.

    CAS  PubMed  Google Scholar 

  182. Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G et al. Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer 2005; 41: 1304–1310.

    PubMed  Google Scholar 

  183. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17: 1134–1140.

    CAS  PubMed  Google Scholar 

  184. Thiel U, Koscielniak E, Blaeschke F, Grunewald TG, Badoglio M, Diaz MA et al. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer 2013; 109: 2523–2532.

    CAS  PubMed  PubMed Central  Google Scholar 

  185. Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006; 107: 3795–3803.

    CAS  PubMed  Google Scholar 

  186. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008; 5: 256–267.

    CAS  PubMed  Google Scholar 

  187. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive mieloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233–5239.

    CAS  PubMed  PubMed Central  Google Scholar 

  188. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917–924.

    PubMed  PubMed Central  Google Scholar 

  189. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous EBV-targeted cytotoxic T-lymphocytes. J Clin Oncol 2005; 23: 8942–8949.

    CAS  PubMed  Google Scholar 

  190. Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M . Is adoptive T-cell therapy for solid tumors coming of age? Bone Marrow Transplant 2012; 47: 1013–1019.

    CAS  PubMed  Google Scholar 

  191. Van Laar J, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–2498.

    CAS  PubMed  Google Scholar 

  192. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler 2012; 18: 825–834.

    CAS  PubMed  PubMed Central  Google Scholar 

  193. Mancardi G, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E et al. Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a phase II trial. Neurology 2015 (e-pub ahead of print).

  194. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116–1124.

    PubMed  Google Scholar 

  195. Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D . Development of a curative treatment within the AML-BFM studies. Klinische Padiatrie 2013; 225 (Suppl 1): S79–S86.

    PubMed  Google Scholar 

  196. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630–639.

    CAS  PubMed  Google Scholar 

  197. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ . A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205–2214.

    CAS  PubMed  Google Scholar 

  198. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR . Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2013; 19: 1021–1025.

    PubMed  PubMed Central  Google Scholar 

  199. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97: 21–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  200. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012; 26: 654–661.

    CAS  PubMed  Google Scholar 

  201. Marks D, Khattry N, Cummins M, Goulden N, Green A, Harvey J et al. Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol 2006; 134: 196–201.

    PubMed  Google Scholar 

  202. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L . Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009; 133: 171–178.

    CAS  PubMed  Google Scholar 

  203. Hasle H . A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol 2014; 166: 23–33.

    PubMed  Google Scholar 

  204. Pulsipher MA, Peters C, Pui CH . High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant 2011; 17 (1 Suppl): S137–S148.

    PubMed  PubMed Central  Google Scholar 

  205. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377–384.

    PubMed  Google Scholar 

  206. Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grumayer R et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 2013; 31: 2736–2742.

    PubMed  Google Scholar 

  207. Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010; 116: 2644–2650.

    CAS  PubMed  Google Scholar 

  208. von Stackelberg A, Volzke E, Kuhl JS, Seeger K, Schrauder A, Escherich G et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur J Cancer 2011; 47: 90–97.

    PubMed  Google Scholar 

  209. Peters C, Cornish JM, Parikh SH, Kurtzberg J . Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pediat Clin North America 2010; 57: 27–46.

    Google Scholar 

  210. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C . Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008; 41 (Suppl 2): S71–S74.

    PubMed  Google Scholar 

  211. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR et al. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant 2011; 46: 950–955.

    CAS  PubMed  Google Scholar 

  212. Meisel R, Klingebiel T, Dilloo D . German/Austrian Pediatric Registry for Stem Cell Transplantation. Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. Blood 2013; 121: 863–865.

    CAS  PubMed  Google Scholar 

  213. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol 2009; 27: 3363–3369.

    PubMed  Google Scholar 

  214. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16: 223–230.

    PubMed  Google Scholar 

  215. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin-Frankfurt-Munster group report. Br J Haematol 2006; 133: 176–182.

    PubMed  Google Scholar 

  216. Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M . Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit 2012; 18: 721–728.

    Google Scholar 

  217. Ulmer A, Tabea Tauer J, Glauche I, Jung R, Suttorp M . TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model. Klinische Padiatrie 2013; 225: 120–126.

    CAS  PubMed  Google Scholar 

  218. Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klinische Padiatrie 2009; 221: 351–357.

    CAS  PubMed  Google Scholar 

  219. Suttorp M, Eckardt L, Tauer JT, Millot F . Management of chronic myeloid leukemia in childhood. Current Hematologic Malignancy Reports 2012; 7: 116–124.

    PubMed  Google Scholar 

  220. Suttorp M, Yaniv I, Schultz KR . Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17 (1 Suppl): S115–S122.

    PubMed  Google Scholar 

  221. de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F . Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014; 167: 33–47.

    PubMed  Google Scholar 

  222. Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M . Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer 2014; 61: 355–357.

    PubMed  Google Scholar 

  223. Locatelli F, Crotta A, Ruggeri A, Eapen M, Wagner JE, Macmillan ML et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood 2013; 122: 2135–2141.

    CAS  PubMed  PubMed Central  Google Scholar 

  224. Madureira AB, Eapen M, Locatelli F, Teira P, Zhang MJ, Davies SM et al. Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantation. Leukemia 2011; 25: 449–454.

    CAS  PubMed  Google Scholar 

  225. Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011; 25: 455–462.

    CAS  PubMed  Google Scholar 

  226. http://www.ebmt.org/Contents/About-EBMT/Who-We-Are/ScientificCouncil/Documents/EBMT_ESID%20GUIDELINES%20FOR%20INBORN%20ERRORS%20FINAL%202011.pdf

  227. Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG et al. Neonatal diagnosis of Severe Combined Immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011; 117: 3243–3246.

    CAS  PubMed  Google Scholar 

  228. Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P et al. Transplantation of haematopoietic stem cells and long term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126: 602–610.

    PubMed  Google Scholar 

  229. Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013; 121: 3981–3987.

    CAS  PubMed  PubMed Central  Google Scholar 

  230. Samarasinghe A, Webb DK . How I manage aplastic anaemia in children. Br J Haematol 2012; 157: 26–40.

    CAS  PubMed  Google Scholar 

  231. Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012; 157: 339–436.

    CAS  PubMed  Google Scholar 

  232. Bhatnagar N, Wynn RF, Velangi M et al. Upfront matched and mismatched unrelated donor transplantation in paediatric idiopathic severe aplastic anaemia: A United Kingdom multicentre retrospective experience. Bone Marrow Transplant 2014; 49 (S1): 0004a.

    Google Scholar 

  233. Samarasinghe S, Marsh J, Dufour C . Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next? Haematologica 2014; 99: 597–599.

    CAS  PubMed  PubMed Central  Google Scholar 

  234. Dufour C, Pillon M, Carraro E, Bhatnagar N, Wynn R, Gibson B et al. Similar outcome of upfront unrelated and matched sibling donor hematopoietic stem cell transplantation in idiopathic aplastic anaemia of childhood and adolescence: A cohort controlled study on behalf of the UK Paediatric BMT Working Party of the Paediatric Diseases Working Party and of the Severe Aplastic Anaemia WP of the EBMT. Blood, Annual Scientific Meeting 2014, 256a.

  235. Fagioli F, Quarello P, Zecca M, Lanino E, Corti P, Favre C et al. Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. Br J Haematol 2014; 165: 673–681.

    PubMed  Google Scholar 

  236. Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122: 1072–1078.

    CAS  PubMed  Google Scholar 

  237. Gaziev J, Marziali M, Isgro A, Sodani P, Paciaroni K, Gallucci C et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood 2013; 122: 2751–2756.

    CAS  PubMed  Google Scholar 

  238. Lucarelli G, Isgro A, Sodani P, Gaziev J . Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012; 2: a011825.

    PubMed  PubMed Central  Google Scholar 

  239. Galambrun C, Pondarre C, Bertrand Y, Loundou A, Bordigoni P, Frange P et al. French multicenter 22 year-experience of Stem Cell transplantation for Beta-Thalassemia Major: lessons and future directions. Biol Blood Marrow Transplant. 2013; 19: 62–68.

    PubMed  Google Scholar 

  240. Angelucci E, Baronciani D . Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008; 93: 1780–1784.

    PubMed  Google Scholar 

  241. Matthes-Martin S, Lawitschka A, Fritsch G, Lion T, Grimm B, Breuer S et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol 2013; 90: 308–312.

    PubMed  Google Scholar 

  242. Lucarelli G, Gaziev J, Isgro A, Sodani P, Paciaroni K, Alfieri C et al. Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transpl 2012; 47: 227–230.

    CAS  Google Scholar 

  243. Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18: 1265–1272.

    PubMed  PubMed Central  Google Scholar 

  244. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood 2012; 119: 2949–2955.

    CAS  PubMed  Google Scholar 

  245. Ladenstein R, Potschger U, Hartman O, Pearson AD, Klingebiel T, Castel V et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41 (Suppl 2): S118–S127.

    CAS  PubMed  Google Scholar 

  246. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007–1013.

    CAS  PubMed  PubMed Central  Google Scholar 

  247. Patel JP, Levine RL . How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012; 2012: 28–34.

    PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful for the advice and helpful comments received from a number of individuals across Europe specializing in the use of haematopoietic SCT. Special thanks to L. Garderet, O. Hermine, S, Montoto, E. Olavarria, S. Robinson, J. Schetelig, N. Schmitz, H. Schouten and A. Tanase.

Author information

Author notes

  1. M Mohty and A Madrigal: Last position in authorship shared by MM and AM.

Authors and Affiliations

  1. Department of Haematology, Institut Catala d’Oncologia, Hospital Duran I Reynals, Barcelona, Spain

    A Sureda & R F Duarte

  2. Universitätsklinikum Frankfurt, Goethe-Universität, Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany

    P Bader

  3. Paediatric Haematology Oncology, Policlinico G.B. Rossi, Verona, Italy

    S Cesaro

  4. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    P Dreger

  5. Clinical And Experimental Hematology Unit. Institute G. Gaslini, Genoa, Italy

    C Dufour

  6. Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands

    J H F Falkenburg

  7. Department of Haematology—BMT, Hopital St Louis, Paris, France

    D Farge-Bancel

  8. Children's BMT Unit, Great North Children's Hospital, Newcastle-Upon-Tyne, UK

    A Gennery

  9. Department of Stem Cell Transplantation, University hospital Eppendorf, Hamburg, Germany

    N Kröger

  10. Haematology and BMT Unit, Cremona, Italy

    F Lanza

  11. Department of Haematological Medicine, King’s College Hospital/King’s College London, London, UK

    J C Marsh

  12. Chaim Sheva Medical Center, Tel-Hashomer, Israel

    A Nagler

  13. Stem Cell Transplantation Unit, St Anna Kinderspital, Vienna, Austria

    C Peters

  14. Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Università di Perugia, Perugia, Italy

    A Velardi

  15. Department of Haematology, H. Saint Antoine, Paris, France

    M Mohty

  16. Anthony Nolan Research Institute, Royal Free and University College, London, UK

    A Madrigal

Authors
  1. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Cesaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R F Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J H F Falkenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Farge-Bancel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Gennery
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Lanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J C Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Velardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Madrigal
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the European Society for Blood and Marrow Transplantation

Corresponding author

Correspondence to A Sureda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sureda, A., Bader, P., Cesaro, S. et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 50, 1037–1056 (2015). https://doi.org/10.1038/bmt.2015.6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.6

This article is cited by

Search

Advanced search

Quick links